This information is intended to provide a general overview of Mantle Cell Lymphoma (MCL). It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health.
Mantle Cell Lymphoma (MCL) is a rare and typically aggressive form of B-cell non-Hodgkin lymphoma. B cells are part of your immune system, originating in the bone marrow. When these cells become cancerous, they develop into a type of cancer called lymphoma. Like all lymphomas, MCL affects the lymphatic system, which includes the lymph nodes, spleen, and bone marrow. A key difference with MCL is that it often also involves the gastrointestinal (GI) tract, including the stomach and colon.
MCL begins when cancerous B-lymphocytes (a type of white blood cell) multiply in the mantle zone—a ring of cells found inside lymph nodes. In approximately 10–20% of patients with MCL, the cancer is initially found in the blood and bone marrow rather than the lymph nodes, a presentation known as the leukemic phase of MCL.
The uncontrolled division of these cancerous B cells can lead to a buildup that causes the lymph nodes to swell. While a small number of people experience a slow-growing form of MCL (indolent), in most cases, the disease is aggressive and requires prompt medical attention. As the cancer spreads to more lymph nodes and the bone marrow, it reaches more advanced stages. MCL is more commonly seen in men and people over the age of 65.
Symptoms of Mantle Cell Lymphoma depend on the areas of the body where the cancer is developing and may not be noticed until the disease is advanced. Symptoms can include:
Often the most noticeable sign, presenting as painless swelling, particularly in the neck, armpits, or groin.
Swelling, pain, or discomfort in the abdomen, which can be caused by an enlarged spleen.
These include extreme, unrelenting tiredness (fatigue), drenching night sweats, and unexplained weight loss that gradually worsens.
Frequent fevers without a clear cause.
Headaches, dizziness, or confusion, which may occur if the cancer spreads to the brain or spinal cord.
Diagnosing Mantle Cell Lymphoma is a precise process. Patients may initially notice swollen lymph nodes, abdominal bloating, or have a high white blood cell count detected during routine blood tests. In some cases, MCL is discovered during a routine colonoscopy.
To confirm an MCL diagnosis, doctors will perform a biopsy of a lymph node, bone marrow, or gastrointestinal tissue. This tissue sample is then analysed with special laboratory tests. These tests look for specific genetic changes, such as in the TP53 gene, and check for abnormal chromosomes in the cells. Finding multiple abnormalities can indicate that the MCL is more aggressive or may not respond as well to certain treatments.
This comprehensive testing process is called risk stratification. It is crucial as it helps your care team determine which treatments are most likely to be effective for you, allowing them to plan personalised care for the best possible outcome.
At SSCHRC, our expert haematopathologists specialise in these conditions, ensuring a precise and timely diagnosis.
While Mantle Cell Lymphoma is not currently considered curable, significant recent advances in treatment have helped many patients achieve longer, improved quality of life. Patients with low- or intermediate-risk MCL often do well for five to eight years or more before the disease may return. In rare instances of slow-growing (indolent), low-risk disease that is not causing symptoms, your doctor may recommend close monitoring without immediate treatment (watchful waiting).
Each treatment plan is highly personalised, taking into account the stage of the lymphoma, the patient's symptoms, overall health, and any other medical conditions. Treatment options include:
Targeted therapies are designed to specifically interfere with the molecules or genes that cancer cells rely on to grow and spread.
Monoclonal antibodies are a form of immunotherapy that targets specific markers on the surface of the MCL cells. This treatment is often used in combination with targeted therapy and/or chemotherapy and has been shown to significantly help patients stay in long-term remission. A combination of immunotherapy and chemotherapy is known as chemoimmunotherapy, which may be followed by maintenance therapy to improve overall survival.
Chemotherapy uses drugs to kill cancer cells, control their growth, or relieve disease-related symptoms.
Radiation therapy uses powerful, focused beams of energy to destroy cancer cells, accurately targeting a tumour while minimising damage to surrounding healthy tissue. It may be offered for MCL that is limited or localised and does not present high-risk features.
A stem cell transplant (also known as a bone marrow transplant) replaces cancerous bone marrow with new, healthy stem cells, which can come from a donor (allogeneic) or the patient (autologous).
Chimeric Antigen Receptor (CAR) T cell therapy is an advanced type of immunotherapy. A patient's own T cells are collected, genetically modified in a lab to specifically target a protein on the cancer cells, and then returned to the patient's body to seek out and attack the cancer.
This is a procedure to remove excess white blood cells (leukocytes) from the blood, often used when patients have a very high white blood cell count.
At SSCHRC, our commitment to research allows us to offer clinical trials for investigational agents, ensuring our patients have access to the newest advancements in MCL care.